U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298434) titled 'Study of VYD2311 for the Prevention of COVID-19' on Dec. 18.
Brief Summary: The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo.
The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a tota...